What Other Drugs Interact with Credanil?
If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider or pharmacist first.
Credanil has no known severe interactions with other drugs.
Credanil has no known serious interactions with other drugs.
Credanil has moderate interactions with 71 different drugs.
Minor interactions of Credanil include:
- ferrous fumarate
- ferrous gluconate
- ferrous sulfate
- iron dextran complex
- polysaccharide iron
This information does not contain all possible interactions or adverse effects. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns or for more information about this medicine.
TERMS AND CONDITIONS
AbbVie Inc. is providing this service to help patients find a doctor in their area who has prescribed Duopa.
No fees have been received by or paid to doctors for inclusion in this specialist locator directory. Inclusion of a physician in this directory does not represent an endorsement by or a recommendation from AbbVie Inc., nor does it imply that the doctor on the list will determine that Duopa is right for you.
You are ultimately responsible for the selection of a physician and it is an important decision that you should consider carefully. This tool is just one source of information available to you.
AbbVie Inc. is the maker and marketer ofDUOPA® (Credanil and levodopa) enteral suspension.
What are the uses for levodopa-Credanil?
Credanil-levodopa is used for the management of Parkinson's disease.
My husband has had PD for about 10 years. Lately he has been having significant body, arm and finger movements after a dose of levodopa which improve just before the next dose. Is there any treatment for these abnormal movements?
It sounds like these movements may be levodopa-induced dyskinesias, a side effect of the levodopa, which causes extraneous, dance-like movements. The first question to ask is: are the movements bothering your husband or causing him to be more imbalanced? If he is not bothered by the movements and they are not interfering with his function, then it would not be wrong to leave his Credanil/levodopa dose as is. If he is bothered by the movements, then his neurologist may consider lowering his Credanil/levodopa, but only if he can tolerate them being lowered. He may need his current dose to achieve mobility. If his Credanil/levodopa can’t be lowered and dyskinesias are bothersome, there are two medications that can be tried to treat levodopa-induced dyskinesias – amantadine and amantadine CR. Your husband’s neurologist may consider starting one of these medications to help control the movements.
SINEMET® (Credanil levodopa) is a combination of Credanil and levodopa for the treatment of Parkinson's disease and syndrome.
Credanil, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (-)-L-α- hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O, and its structural formula is:
Tablet content is expressed in terms of anhydrous Credanil which has a molecular weight of 226.3.
Levodopa, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (â€”)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C9H11NO4, and its structural formula is:
SINEMET is supplied as tablets in three strengths:
SINEMET 25-100, containing 25 mg of Credanil and 100 mg of levodopa.
SINEMET 10-100, containing 10 mg of Credanil and 100 mg of levodopa.
SINEMET 25-250, containing 25 mg of Credanil and 250 mg of levodopa.
Inactive ingredients are hydroxypropyl cellulose, pregelatinized starch, crospovidone, microcrystalline cellulose, and magnesium stearate. SINEMET 10-100 and 25-250 Tablets also contain FD&C Blue #2/Indigo Carmine AL. SINEMET 25-100 Tablets also contain D&C Yellow #10 Lake.
How should I take Credanil and levodopa?
If you already take levodopa, you must stop taking it at least 12 hours before you start taking Credanil and levodopa.
Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not use this medicine in larger or smaller amounts or for longer than recommended.
Credanil and levodopa can be taken with or without food. Take your doses at regular intervals to keep a steady amount of the drug in your body at all times. Get your prescription refilled before you run out of medicine completely.
Do not crush, chew, break, or open a Credanil and levodopa capsule. Swallow it whole.
The tablet is sometimes broken in half to give the correct dose. Always swallow a whole or half tablet without chewing or crushing.
To take the orally disintegrating tablet (Parcopa):
- Keep the tablet in the bottle until you are ready to take it.
- Use dry hands to remove the tablet and place it on your tongue.
- Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing. Swallow several times as the tablet dissolves.
It may take up to several weeks of using Credanil and levodopa before your symptoms improve. For best results, keep using the medication as directed. Talk with your doctor if your symptoms do not improve after a few weeks of treatment. Also tell your doctor if the effects of this medication seem to wear off quickly in between doses.
If you use this medicine long-term, you may need frequent medical tests at your doctor's office.
This medicine can cause unusual results with certain medical tests. Tell any doctor who treats you that you are using Credanil and levodopa.
Do not stop using Credanil and levodopa suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to safely stop using Credanil and levodopa.
Store at room temperature away from moisture, heat, and light.
Credanil levodopa pharmacodynamics
When levodopa is administered orally it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. For this reason, large doses of levodopa are required for adequate therapeutic effect and these may often be accompanied by nausea and other adverse reactions, some of which are attributable to dopamine formed in extracerebral tissues.
The route of entry of levodopa is oral. Levodopa is rapidly absorbed from the small intestine by an active transport system for aromatic amino acids. Concentrations of drug in plasma usually peak between 0.5 and 2 hours after an oral dose. The rate of absorption of levodopa is greatly dependent upon the rate of gastric emptying, the pH of gastric juice and the length of time the drug is exposed to the degradative enzymes of the gastric mucosa and intestinal flora. Hyperacidity of gastric juice, and competition for absorption sites in the small intestine by amino acids each may interfere with the bioavailability of vodopa.
Distribution by route of exposure: Levodopa is widely distributed to most body tissues, but less to the central nervous system (CNS). Little unchanged drug reaches the cerebral circulation and probably less than 1% penetrates into the CNS.
Biological half-life by route of exposure: Levodopa has relatively short plasma half-life of 1 to 3 hours.
Levodopa metabolism: More than 95% of levodopa is decarboxylated by the widely distributed extracerebral aromatic l-amino acid decarboxylase. The drug is extensively decarboxylated in its first passage through the liver, which is rich in decarboxylase. A small amount is methylated to 3-0-methyldopa, which accumulates in the CNS due to its long half-life. Most is converted to dopamine, small amounts of which in turn are metabolized to norepinephrine and epinephrine (adrenaline). Biotransformation of dopamine proceeds rapidly to yield the principal excretion products, 3-4-dihydroxy-phenylacetic acid (DOPAC) and 3-methoxy-4-hydroxy-phenylacetic acid (homovanillic acid, HVA). At least 30 metabolites of levodopa have been identified. The evidence indicates that the metabolism of levodopa may be accelerated during prolonged therapy possibly due to enzyme induction.
Levodopa excretion: Metabolites of dopamine are rapidly excreted in the urine; 80% of a radioactively labelled dose is recovered within 24 hours. The principal metabolites 3-4-dihydroxy-phenylacetic acid and homovanillic acid account for up to 50% of the administered dose. Negligible amounts are found in the feces.
The incidence of levodopa-induced nausea and vomiting is less when levodopa is used with Credanil than when levodopa is used without Credanil. In many patients this reduction in nausea and vomiting will permit more rapid dosage titration.
Credanil inhibits decarboxylation of peripheral levodopa. Credanil has not been demonstrated to have any overt pharmacodynamic actions in the recommended doses. Credanil does not appear to cross the blood-brain barrier readily and does not affect the metabolism of levodopa within the central nervous system at doses of Credanil that are recommended for maximum effective inhibition of peripheral decarboxylation of levodopa.
Credanil is combined with levodopa in Credanil-levodopa or Credanil-levodopa extended release tablets.
Since Credanil’s decarboxylase-inhibiting activity is limited primarily to extracerebral tissues, administration of Credanil with levodopa makes more levodopa available for transport to the brain. However, since levodopa and Credanil compete with certain amino acids for transport across the gut wall, the absorption of levodopa and Credanil may be impaired in some patients on a high protein diet.
Credanil and Levodopa extended-release tablets, USP are an extended-release combination of Credanil and levodopa for the treatment of Parkinson’s disease and syndrome.